Close integration of clinical and basic research yields high-quality outcomes  

作　　者：Xiaoling Liang 梁小玲(State Key Laboratory of Ophthalmology,Zhongshan Ophthalmic Center,Sun Yat-sen University,Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science,Guangzhou 510060,China)

机构地区：[1]State Key Laboratory of Ophthalmology,Zhongshan Ophthalmic Center,Sun Yat-sen University,Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science,Guangzhou 510060,China

出　　处：《Eye Science》2024年第4期287-289,共3页眼科学报(英文版)

摘　　要：Emily Chew's article,“The Journey to Discovery for Treatments of Retinal Hemangioblastomas Associated with von Hippel-Lindau Disease,”vividly narrates the process of discovering and clinical application of therapeutic agents for retinal hemangioblastomas linked to von Hippel-Lindau(VHL)disease.The successful development of this drug stands as a quintessential example illustrating the effective integration of“From Bedside to Bench,Then Bench to Bedside”approach in clinical and basic scientific research.This approach involves clinicians identifying problems in clinical practice,laboratory scientists investigating the disease mechanisms to pinpoint crucial points,subsequently developing new drugs for clinical use,and these drugs entering clinical trials and application.

关 键 词：CLINICAL drugs INTEGRATION 

分 类 号：R73[医药卫生—肿瘤]